ArticleCase reports in hepatology2026
A Case Report of Direct-Acting Antiviral Therapy for Chronic Hepatitis C in a Patient With Dementia Treated in Collaboration With Multiple Specialists.
Article in Case reports in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Case Report of Direct-Acting Antiviral Therapy for Chronic Hepatitis C in a Patient With Dementia Treated in Collaboration With Multiple Specialists.Case reports in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 77-year-old female with dementia was transferred from her family clinic to our hospital with a 2-day history of appetite loss and was diagnosed with pneumonia and urinary tract infection upon admission. Laboratory investigation revealed hepatitis C virus antibody positivity and an elevated hepatitis C virus ribonucleic acid level of 3.6 Log IU/mL; therefore, direct-acting antiviral therapy was initiated. Although the patient requested treatment for hepatitis C, managing her medication was difficult because of dementia, as she lived alone and had no family, which required her to take medication under supervision, even on holidays. After discharge, the patient was treated with glecaprevir hydrate and pibrentasvir for 8 weeks by a hepatologist with biweekly visits to monitor adverse events. The hepatitis C virus ribonucleic acid test result was negative after 4 weeks of treatment, and we asked her family physician to confirm a sustained virologic response. Collaboration among multiple specialists, both within and outside the hospital, is essential for facilitating the treatment of such patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.